Loading clinical trials...

COMPLETEDPHASE1

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

An Open-Label, Single-Dose, Fixed-Sequence Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986036 Administered to the Abdomen and Upper Arm in Healthy Participants

NCT03445208•Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

This is a study of experimental medication BMS-986036 given to healthy participants.

Eligibility

Age

21 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
•Healthy participant, as determined by no clinically significant deviations from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
•BMI of 18 to ≤ 40 kg/m2

Exclusion Criteria

•Presence of any factors that would predispose the participant to infection (eg, extensive periodontal disease that warrants surgical or medical treatment, unhealed open wounds)
•Any bone trauma (fracture) or bone surgery (i.e. hardware placement, joint replacement, bone grafting, or amputation) within 3 months of study drug administration
•Known or suspected autoimmune disorder, excluding vitiligo
•Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status
•Any significant acute or chronic medical illness
•Current or recent (within 3 months of study drug administration) gastrointestinal disease
•Any major surgery within 6 weeks of study drug administration
•History of diabetes mellitus

Locations (1)

PRA Health Sciences

Salt Lake City, Utah, United States

Key Dates

Start Date

February 14, 2018

Primary Completion Date

May 2, 2018

Completion Date

May 2, 2018

Last Updated

March 19, 2020

Enrollment

ACTUAL participants

Conditions

Hepatic CirrhosisLiver FibrosisNonalcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis

Interventions

BMS-986036

DRUG

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444

Metabolic Dysfunction Associated Steatohepatitis (MASH)Liver Fibrosis

View study

RECRUITING

Rapid Breath-hold Quantitative Macromolecular Proton Fraction Imaging for Liver Fibrosis

NCT04429100

Liver Fibrosis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 19, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

Inclusion Criteria

Exclusion Criteria

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Rapid Breath-hold Quantitative Macromolecular Proton Fraction Imaging for Liver Fibrosis

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

Biomarkers in the Diagnosis and Prognosis of NAFLD

Endosonographic Shear Wave Elastography to Assess Liver and Splenic Fibrosis